BACKGROUND INFORMATION ON THE PROCEDURE 
1.  Submission of the dossier 
The  applicant  Alexion  Europe  SAS  submitted  on  25  September  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Soliris,  through  the  centralised 
procedure falling within the Article 3(1) and point 1 and 4 of Annex of Regulation (EC) No 726/2004. 
The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 30 March 2006. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or 
studies 
Soliris  was  designated  as  an  orphan  medicinal  product  EU/3/03/166  on  17  October  2003  in  the 
following indication: treatment of patients with paroxysmal nocturnal haemoglobinuria. The calculated 
prevalence of this condition was 0.01 per 100,000 EU population. 
The applicant applied for the following indication: Soliris (eculizumab) is indicated for the treatment 
of patients with paroxysmal nocturnal hemoglobinuria (PNH). 
Protocol Assistance: 
The applicant received Protocol Assistance from the CHMP on 18 November 2004 and 23 February 
2006.  The  Protocol  Assistance  pertained  to  biological,  toxico-pharmacological  and  clinical 
development aspects of the dossier. 
Licensing status: 
A new application was filed in the following countries: U.S.A. 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and their evaluation teams were: 
Rapporteur:  Gonzalo Calvo Rojas (ES) 
Co-Rapporteur:  Eric Abadie (FR) 
2.  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
Accelerated Assessment procedure was agreed-upon by CHMP on 29 June 2006. 
The application was received by the EMEA on 25 September 2006. 
The procedure started on 25 October 2006. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 21 January 
2007.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
23 January 2007. 
During  the  meeting  on  19-22  February  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 22 February 2007. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  
20 March 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 10 April 2007. 
During the meeting on 23-26 April 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
©EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
Marketing  Authorisation  to  Soliris  on  26  April  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 25 April 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 20 June 2007. 
©EMEA 2007 
2/2 
